Nanexa

Nanexa AB (publ) today announced that the annual report for 2022 has been published and is available on the company's website https://nanexa.com/en/financial-reports/.

”2022 was a year in which we took large steps towards commercialisation of our PharmaShell system. We signed four new evaluation agreements and in particular one with Novo
Nordisk, which also included a 4 MUSD payment for a specific exclusivity during the evaluation period. We have also made important progress in our own development projects in which we have now taken NEX-20 (one-month depot of lenalidomide) into the clinical phase and have initiated a new project with tremendous potential in type 2 diabetes, NEX-22 (one-month depot of liraglutide). In the NEX-18 project, we have identified possible improvements to the formulation in order to reduce skin reactions and continue product development. An opportunity to demonstrate greater efficacy than the original product Vidaza was also identified in discussions with our Scientific Advisory Board, an opportunity based on our long release profile that we consider to be worth evaluating.”, said David Westberg, CEO of Nanexa.